Sangamo Therapeutics, Inc.
ENGINEERED CLEAVAGE HALF-DOMAINS
Last updated:
Abstract:
Disclosed herein are engineered cleavage half-domains; fusion polypeptides comprising these engineered cleavage half-domains; polynucleotides encoding the engineered cleavage half-domains and fusion proteins; and cells comprising said polynucleotides and/or fusion proteins. Also described are methods of using these polypeptides and polynucleotides, for example for targeted cleavage of a genomic sequence.
Status:
Application
Type:
Utility
Filling date:
4 Oct 2021
Issue date:
12 May 2022